Maeda T, Hiura A, Uehara J, Toyoshima R, et al. Early tumor response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma. Br J Dermatol 2021 Nov 8. doi: 10.1111/bjd.20879.
PMID: 34747503